29 results
8-K
MIRA
Mira Pharmaceuticals Inc
19 Jul 24
Other Events
5:12pm
. Ketamir-2 is under investigation for its potential in treating neurological and neuropsychiatric disorders, including depression, treatment-resistant
10-K
2023 FY
MIRA
Mira Pharmaceuticals Inc
1 Apr 24
Annual report
7:00am
pending oral ketamine analog under pre-clinical investigation to potentially deliver ultra-rapid antidepressant effects, providing hope for individuals … as part of the IND.
An IND is a request for authorization from the FDA to ship an investigation product and then administer it to humans and must
8-K
MIRA
Mira Pharmaceuticals Inc
7 Mar 24
Other Events
4:45pm
investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.
In its prior public
8-K
EX-10.1
26fjzx2yr6xfb2kk
20 Nov 23
MIRA Pharmaceuticals Announces Exclusive Licensing Agreement for Oral Ketamine Analog, Ketamir-2
8:10am
8-K
EX-99.1
r8oo5lbt4t3 8mtl36
20 Nov 23
MIRA Pharmaceuticals Announces Exclusive Licensing Agreement for Oral Ketamine Analog, Ketamir-2
8:10am
10-Q
nif0k1ebzmsn7a762m8t
15 Sep 23
Quarterly report
4:45pm
8-K
EX-99.2
fep7 em7h7
7 Aug 23
MIRA Pharmaceuticals, Inc. Announces Pricing of $8.9 Million Initial
5:14pm
8-K
EX-99.1
jkcet0vxfn z1e2
7 Aug 23
MIRA Pharmaceuticals, Inc. Announces Pricing of $8.9 Million Initial
5:14pm
8-K
EX-1.1
agd4ubqg
7 Aug 23
MIRA Pharmaceuticals, Inc. Announces Pricing of $8.9 Million Initial
5:14pm
8-K
EX-4.1
fvvkz0xf 89
7 Aug 23
MIRA Pharmaceuticals, Inc. Announces Pricing of $8.9 Million Initial
5:14pm
424B4
3kpya1979ekd25ac5kc
4 Aug 23
Prospectus supplement with pricing info
1:01pm
424B1
wzrlbme17kw8
4 Aug 23
Prospectus with pricing info
12:59pm